SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response
Нема приказа
Аутори
Rosić, JovanaDragičević, Sandra
Miladinov, Marko
Despotović, Jovana
Bogdanović, Aleksandar
Krivokapić, Zoran
Nikolić, Aleksandra
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primar...y tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.
Кључне речи:
SMAD7 / SMAD4 / Neoadjuvant chemoradiotherapy / Metastases / Colorectal cancerИзвор:
Experimental and Molecular Pathology, 2021, 123Издавач:
- Academic Press Inc Elsevier Science, San Diego
Финансирање / пројекти:
- strategic project of the Serbian Academy of Sciences and Arts [02-2019, F-69]
DOI: 10.1016/j.yexmp.2021.104714
ISSN: 0014-4800
PubMed: 34717960
WoS: 000720568100003
Scopus: 2-s2.0-85118270674
Колекције
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Rosić, Jovana AU - Dragičević, Sandra AU - Miladinov, Marko AU - Despotović, Jovana AU - Bogdanović, Aleksandar AU - Krivokapić, Zoran AU - Nikolić, Aleksandra PY - 2021 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1469 AB - Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value. PB - Academic Press Inc Elsevier Science, San Diego T2 - Experimental and Molecular Pathology T1 - SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response VL - 123 DO - 10.1016/j.yexmp.2021.104714 ER -
@article{ author = "Rosić, Jovana and Dragičević, Sandra and Miladinov, Marko and Despotović, Jovana and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra", year = "2021", abstract = "Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.", publisher = "Academic Press Inc Elsevier Science, San Diego", journal = "Experimental and Molecular Pathology", title = "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response", volume = "123", doi = "10.1016/j.yexmp.2021.104714" }
Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology Academic Press Inc Elsevier Science, San Diego., 123. https://doi.org/10.1016/j.yexmp.2021.104714
Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology. 2021;123. doi:10.1016/j.yexmp.2021.104714 .
Rosić, Jovana, Dragičević, Sandra, Miladinov, Marko, Despotović, Jovana, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response" in Experimental and Molecular Pathology, 123 (2021), https://doi.org/10.1016/j.yexmp.2021.104714 . .